SCYNEXIS Inc
Închisă
4.77 3.47
Rezumat
Modificarea prețului
24h
Minim
4.59
Maxim
4.95
Venit | -34M -21M |
|---|---|
EPS | -0.418 |
Marjă de profit | 65.741 |
Angajați | 18 |
EBITDA | -29M -17M |
Recomandări | Cumpărare |
|---|---|
Prognoză pe 12 luni | +473.77% upside |
Capitalizare de piață | 53M |
|---|---|
Deschiderea anterioară | 1.3 |
Închiderea anterioară | 4.77 |
SCYNEXIS Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
SCYNEXIS Inc Așteptări
Obiectiv de preț
By TipRanks
473.77% sus
Prognoză pe 12 luni
Medie 28 USD 473.77%
Maxim 32 USD
Minim 24 USD
În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSCYNEXIS Inc - Dist în ultimele 3 luni.
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre SCYNEXIS Inc
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
